Bioprinting suppliers: who is still selling, what it costs, and who has already left

The short answer: no bioprinter vendor publishes an instrument price, most publish consumable prices, and the category has a documented history of exits that a buyer needs to see before signing a capital purchase order. One of those exits reached its end-of-service-life date six weeks before this page was written, and the software those machines depend on has been offline since June.

That last fact is the reason this directory exists in this form. A bioprinter is a capital instrument with a cloud-dependent software stack and a proprietary consumable ecosystem. The failure mode is not that the printer breaks; it is that the vendor stops.

The directory

The exits, with dates

A directory that records only who is open will send you an RFQ into a dead inbox. This category has the clearest exit record of anything we broker, and the direction of travel is worth reading.

Allevi (3D Systems). The company’s own discontinued-products notice, status last updated 28 August 2026, states three things that matter:

1. Production of Allevi bioprinters was discontinued effective 27 July 2023.
2. End of service life for the Allevi bioprinters was 27 July 2026 — a date that has now passed.
3. The Bioprint software has been offline since 23 June due to server issues, with the company working to restore the servers and, in parallel, to develop an offline version of the software that can be used without server access.

Read those together and you have the clearest possible illustration of platform risk in this category. Instruments were sold, production stopped, service life ended, and the cloud-dependent software that operates them went dark — and the offline fallback is being developed after the outage, not before. To the company’s credit, it honoured warranty obligations through the standard warranty periods and kept the online shop running for remaining consumables. But anyone who bought an Allevi in 2022 now owns a machine past end of service life whose control software depends on a server outage being resolved.

Systemic Bio (3D Systems) was shut down in July 2025. It was the production-scale bioprinting business built out of the Allevi acquisition.

The strategic reading matters more than either individual event. The obvious incumbents for a print-bureau model of tissue manufacture — a JLCPCB for living parts — were assembled inside one public company and then retreated from it within two years. That is not proof the model cannot work. It is evidence that it was tried at scale, with capital, and stopped.

Nobody publishes an instrument price, and one vendor accidentally tells you why

The only instrument price we could find anywhere in this category is historical: Brinter 1 at EUR 24,900, reported at the November 2021 launch of the cheaper Brinter Core. Five years old, from trade press rather than the vendor, and for a product whose current pages return 404.

Everything else is quote-gated. CELLINK’s storefront is the cleanest demonstration: it will sell you a $479 bioink and a $99 pack of sterile cartridges through a public API, and returns no price at all for the BIO X or BIO X6. REGEMAT goes further and gates even consumable prices behind a customer login, while stating “Contact Us for a Quote” on the printer itself.

The reason is structural rather than evasive. A bioprinter quote is an instrument plus printheads plus a software licence plus a service contract, and the printhead configuration alone can double the system. There is no single number to publish. But the consequence for a buyer is real: you cannot compare platforms on capital cost from public information, and vendors know that the first comparable number appears only after you have entered a sales process.

Force the comparison the same way we recommend for organ-chip platforms. Ask every vendor for the same five figures: base instrument; every printhead you actually need, itemised; software licence terms and whether it is perpetual or annual; annual service contract; and consumable cost per print at three annual volumes. Then ask the two questions specific to this category, below.

The two questions that are specific to bioprinting

Does the software require a server?

This is now a documented failure mode, not a hypothetical one. Ask, in writing, whether the control software runs fully offline, whether a perpetual offline licence exists, and what happens to the instrument if the vendor’s servers are unavailable. A machine whose slicer or job queue lives in a cloud account is a machine you rent.

Is the material ecosystem open or closed?

CELLINK sells both its own bioinks and, through the Advanced BioMatrix line, a broad collagen range — but the cartridges are proprietary and priced accordingly. REGEMAT sells its own hydrogels, thermoplastics and initiators as a 52-item catalogue. Brinter’s stated pitch is openness to third-party materials.

A closed ecosystem is not automatically bad — matched materials are validated against the hardware and that saves real time. But it prices your consumable stream for the life of the instrument, and it is the mechanism by which a discontinued platform becomes an unusable one.

What the consumables actually cost

CELLINK is the only vendor exposing a public store API, so it sets the visible reference for the category. Live-verified 2026-09-01:

Two observations a buyer should carry into a quote. First, the $3,695 bioink starter package is roughly eight times a single bioink — it is a validated materials set, and its existence tells you that material selection is the hard part of getting a first print to work. Second, the $369 HEPA filter is a recurring cost, as are cartridges at $99 per sterile pack. Model consumables per print, not per year, and multiply by the number of failed prints you expect while developing a protocol, which early on is most of them.

The four Lifeink collagen bioinks, the GelMA 95% DS stock solution and PhotoCol methacrylated collagen are all quote-only on the same storefront. Full matrix pricing is in hydrogel and ECM suppliers.

Technology choice, briefly

The three architectures are not interchangeable and the differences are larger than any vendor comparison suggests.

• Extrusion (CELLINK BIO X, REGEMAT, Brinter, the former Allevi) is the workhorse. Multi-material by printhead, tolerant of viscous inks and high cell densities, and the resolution is set by nozzle gauge and shear tolerance rather than optics. Shear stress at the nozzle is a real cell-viability cost.
• Light-based (LUMEN X, BIONOVA X, Quantum X bio) buys resolution — down to a stated 10 µm feature size on BIONOVA X, with direct in-well printing. It constrains you to photo-crosslinkable materials and an initiator your cells tolerate, which is a materials problem before it is an optics problem.
• Volumetric (Readily3D Tomolite) forms the whole construct at once from intersecting light beams. Published work reports liver organoid constructs in under 20 seconds. No layer interfaces and no nozzle shear, at the cost of a narrower materials window and a fundamentally different design workflow.
• Single-cell (Fluicell Biopixlar) is a different category again — placing individual cells in defined patterns rather than depositing bulk material. If your question is about cell-to-cell arrangement rather than construct geometry, nothing on the extrusion list substitutes for it.

Where bioprinting does not currently help

Two honest limits, stated because vendor marketing tends not to.

It does not solve the contractile muscle problem. No bioprinter in this directory produces a force-specified, mechanically anchored muscle construct. The devices that cast contractile tissue against anchors are a different product category entirely — post-and-pillar plates from eNUVIO and Curi Bio, covered in 3D muscle culture devices and the muscle actuator sourcing guide. A printed muscle construct still has to be matured and anchored, and that is where the difficulty lives.

Nobody in this directory sells printing as a service. Advanced Solutions does not advertise a contract print service. CELLINK lists a services line but sells instruments as the primary product. Aspect Biosystems runs the most sophisticated platform on this list exclusively for its own therapeutic pipeline. If your requirement is “twelve constructs, printed to this geometry, delivered” — rather than “a machine to print them on” — that capability retreated from this market with Systemic Bio and has not been replaced.

What we would ask before a capital purchase

1. Does the control software run fully offline, and is a perpetual offline licence available?
2. What is the stated end-of-service-life policy, and how long is support guaranteed after a discontinuation?
3. Full quote: instrument, every required printhead itemised, software licence terms, service contract, and consumable cost per print at three annual volumes.
4. Can the instrument use third-party materials without voiding support?
5. What cell viability does the vendor measure immediately post-print, at what density, in which material, with which nozzle — and will they share the raw data?
6. Resolution as demonstrated with cells in the material you intend to use, not with a test resin.
7. Sterility workflow: does the printer go in a hood, or does it have a certified enclosure, and what does recertification cost?
8. Who else at your institution owns one, because a shared instrument with an experienced operator beats a new one with none.
9. What happens to the construct after printing — because maturation, not printing, is usually the schedule.

Related pages

For the materials that go through these machines, see hydrogel and ECM suppliers. For the alternative route when you need a specific geometry — machining a device rather than printing a tissue — see custom microfluidic device fabrication and the fabrication cost analysis.

We maintain this directory because we broker across it. We sell no instrument, hold no reseller agreement, and have no interest in whether you buy a printer. Where the honest answer is that a $440 casting plate and a pipette will produce the construct you described, we will say that.